Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

Solbritt Rantapää‐Dahlqvist, B.A.W. de Jong, Ewa Berglin et al. · Arthritis & Rheumatism · 2003 · 2K citations

Life Sciences, Immunology, Internal Medicine +17

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Kevan C. Herold, Brian N. Bundy, S. Alice Long et al. · New England Journal of Medicine · 2019 · 1.1K citations · Full text

Medicine, Immunology, Internal Medicine +17

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

Hajime Uno, Brian Claggett, Lü Tian et al. · Journal of Clinical Oncology · 2014 · 782 citations · Full text

Public Health, Biostatistics, Oncology +16

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study

F. van Gaalen, Suzanne P. Linn-Rasker, W J van Venrooij et al. · Arthritis & Rheumatism · 2004 · 642 citations · Full text

Life Sciences, Immunology, Internal Medicine +17